SOX2 and sarcoma: Survival analysis revealed that higher expression of SOX2, NANOG, and MYC but not OCT4 (POU5F1) or KLF4 is associated with significantly reduced survival in sarcoma patients (Figure 1A; Supplementary Figure S1A).